FDA approves psilcocyin as breakthrough drug for depression
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer
Efficacy of Psilocybin With Obsessive-Compulsive Disorder
This study showed that psilocybin produced substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer, and that mystical-type experiences on session days mediated the effect of psilocybin dose on therapeutic outcomes. Participants, staff, and community observers rated participant moods, attitudes, and behaviors throughout the study. High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety. At 6-month follow-up, these changes were sustained, with about 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety. Study participants attributed improvements in attitudes about life/self, mood, relationships, and spirituality to the high-dose experience, with >80% endorsing moderately or greater increased well-being/life satisfaction, which was further supported by community observer ratings showing corresponding changes.
Mobile App to help aid a trip
Read TripApp Review
A trove of more than 60,000 pages of information about psychoactive drugs, plants, chemicals, and technologies.
Resources for safe, structured, and responsible psychedelic use.
Canadian University Psilocybin Research
University of Toronto Psychedelic Studies Research Program
Canadian Ongoing psilocybin research project based out of Victoria, BC.
Canadians suffering from end-of-life distress became the first individuals to legally access an exemption to access psilocybin therapy.